Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABBV, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Atogepant FDA approved Sep 2021 · Qulipta |
Migraine | Phase 4 · NCT06972056 | Recruiting |
| Onabotulinumtoxina FDA approved Dec 1991 · Botox Cosmetic |
Masseter Muscle Prominence | Phase 3 · NCT06068855 | Completed |
| Upadacitinib FDA approved Aug 2019 · Rinvoq |
Hidradenitis Suppurativa | Phase 3 · NCT05889182 | Active not recruiting |
| Venetoclax FDA approved Apr 2016 · Venclexta |
Acute Myeloid Leukemia | Phase 3 · NCT05183035 | Active not recruiting |
| Telisotuzumab Vedotin FDA approved May 2025 · Emrelis |
Non Small Cell Lung Cancer | Phase 3 · NCT04928846 | Recruiting |
| Risankizumab FDA approved Apr 2019 · Skyrizi |
Psoriatic Arthritis | Phase 2 · NCT06865105 | Recruiting |
| Ubrogepant FDA approved Dec 2019 · Ubrelvy |
Healthy Volunteer | Phase 1 · NCT07680686 | Completed |
| Tavapadon FDA approved Sep 2026 · Juvmo |
Parkinson Disease | N/A · NCT07158827 | No longer available |
| Propranolol | Migraine | Phase 4 · NCT06972056 | Recruiting |
| Investigator's Choice Chemotherapy | Diffuse Large B-cell Lymphoma | Phase 3 · NCT04628494 | Active not recruiting |
| Fludarabine | Acute Myeloid Leukemia | Phase 3 · NCT05183035 | Active not recruiting |
| Etentamig | Relapsed or Refractory Multiple Myeloma | Phase 3 · NCT07728188 | Recruiting |
| ABBV-722 | Systemic Sclerosis | Phase 2/3 · NCT07933211 | Not yet recruiting |
| Vincristine | B-Cell Non-Hodgkin Lymphoma | Phase 1/2 · NCT05201248 | Active not recruiting |
| Bendamustine | Diffuse Large B-Cell Lymphoma | Phase 1/2 · NCT04663347 | Active not recruiting |
| Zanubrutinib | Chronic Lymphocytic Leukemia | Phase 2 · NCT07734038 | Recruiting |
Also used in these trials (approved or third-party drugs, not ABBV's own candidates): Topiramate, Dexamethasone, Pomalidomide, Gemtuzumab Ozogamicin, Epcoritamab, Docetaxel Anhydrous, Daratumumab, Cytarabine, Carfilzomib, Azacitidine, Bimatoprost, Teclistamab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABBV holds $10.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABBV files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 148,974,939 | 8.43% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 132,924,058 | 7.52% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 82,815,387 | 4.69% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 49,001,331 | 2.77% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 47,503,777 | 2.69% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 45,333,436 | 2.56% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 38,398,732 | 2.17% | 2026-09-30 |
| Capital Research Global Investors | Institution (13F) | 31,115,872 | 1.76% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 26,386,673 | 1.49% | 2026-09-30 |
| Azita Saleki-gerhardt EVP, CHIEF OPERATIONS OFFICER · +20,312 options |
Insider | 204,373 | 0.01% | 2026-02-27 |
| Robert A. Michael CHAIRMAN OF THE BOARD AND CEO, Director · +81,251 options |
Insider | 178,737 | 0.01% | 2026-02-27 |
| Thomas C Freyman Director |
Insider | 133,810 | 0.01% | 2026-05-08 |
Share count 1,767,616,306 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-12 filed 2026-11-12 |
Stewart Jeffrey Ryan |
Gift (G) | 3,450 | – | 79,721 |
| 2026-11-09 filed 2026-11-12 |
Stewart Jeffrey Ryan |
Option exercise (M) | 16,070 | $114.36 | 99,241 |
| 2026-11-09 filed 2026-11-12 |
Stewart Jeffrey Ryan |
Option exercise (M) | 24,549 | $93.50 | 123,790 |
| 2026-11-09 filed 2026-11-12 |
Stewart Jeffrey Ryan |
Sale (S) | 40,619 | $293.60 | 83,171 |
| 2026-11-09 filed 2026-11-12 |
Stewart Jeffrey Ryan |
Option exercise (M) | 16,070 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABBV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →